Aureka Biotechnologies Secures $100 Million in Series B Funding
Aureka Biotechnologies, a company specializing in AI-driven drug discovery, has successfully raised $100 million in a Series B funding round. This round was led by Granite Asia, with additional participation from HighLight Capital, MPCi, and NRL Capital. The company is headquartered in Laguna Hills, California, United States.
Enhancing AI-Driven Drug Discovery
Founded by Weian Zhao, Aureka Biotechnologies aims to transform the drug discovery process through its AI-native platform. The platform integrates foundation models, AI agents, digital biology, and experimental infrastructure. The company’s approach, known as "Lab-in-the-Loop," allows AI models to propose molecular designs and scientific hypotheses that are then experimentally validated, creating a feedback loop for continuous model improvement.
Strategic Use of Funds
The newly acquired funds will be directed towards advancing Aureka's biological foundation models and expanding its AI-native drug discovery infrastructure. This includes efforts in de novo molecular design, biological structure modeling, and function prediction. Additionally, Aureka plans to enhance its Lab-in-the-Loop platform to further integrate AI models with proprietary single-cell functional screening and high-throughput validation systems.
Leadership Insights
CEO Weian Zhao emphasized the impact of this funding round: "When leading biological foundation models are genuinely combined with R&D infrastructure that can run at scale, we are no longer simply making one step of drug discovery more efficient. We are building the next-generation drug discovery engine, one that can understand, generate and predict biological systems."
Future Developments
With partnerships already established with several global pharmaceutical companies, Aureka Biotechnologies is well-positioned to leverage its AI-driven platform for significant advancements in drug discovery. The company has reported substantial revenue generation over the past two years, indicating a strong market presence and potential for future growth.